LOS ANGELES, 15 August 2024 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Pursue“), a biotechnology company focused on developing highly purified, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of an experienced life sciences accounting and finance professional David House as Senior Vice President, Finance, effective 16.Augustth. Armatas Corporate Controller, Richard Rychlikwill retain the position of the controller.
“We are delighted to welcome David to the Armata team,” said Dr. Deborah BirxCEO of Armata. “David’s extensive experience and track record in senior accounting and finance roles in clinical and commercial stage life science companies will benefit us as we continue to advance our two distinct programs – AP-PA02 and AP-SA02 – and prepare to begin pivotal trials next year. This is an exciting time at Armata and the addition of David to our leadership team helps ensure we are optimally positioned for long-term success as we work to introduce an exciting new class of anti-infectives to treat severe, drug-resistant bacterial infections.”
Prior to joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting for ZO Skin Health, Inc., a multi-channel physician-prescribed skin care company. October 2018 To June 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a critical role in the company’s acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration in mergers and acquisitions. Mr. House’s experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization, where he served as controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the “SEC“) Reporting.
Mr. House’s career also includes positions at Viant, Inc. (DSP), Sourcing Solutions, LLC and Apria Healthcare (APR), where he held various accounting and financial management positions. Earlier in his career, Mr. House worked as a Senior Auditor at Windes, an accounting firm. There, he conducted comprehensive audits for public, private and non-profit companies and was involved in SEC filings and internal control assessments. Mr. House holds a Bachelor of Arts in Business Administration with an emphasis in Accounting from California State University, Fullerton. He obtained his California license as a certified public accountant, which is currently inactive.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureusand other pathogens. Armata is committed to advancing phage therapy and has extensive expertise in drug development from the laboratory to the clinic, including in-house phage-specific cGMP manufacturing.
Forward-looking statements
This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or future financial performance of Armata and involve known and unknown risks, uncertainties and other factors that may cause Armata’s actual results, performance or events to differ materially from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “may,” “estimate,” “expect,” “intend,” “could,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms and similar expressions. These forward-looking statements reflect management’s views and beliefs with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties, including risks related to Armata’s development of bacteriophage-based therapies; the ability to staff and maintain its manufacturing facilities in full compliance with current good manufacturing practices; the ability to achieve expected milestones in the development and testing of the respective product; the ability to be a leader in the development of phage-based therapeutics; the ability to achieve its vision, including improvements through engineering and successful clinical trials; the ability to successfully complete preclinical and clinical development of its product candidates, obtain regulatory approval of its product candidates and bring any approved products to market on the expected timeframe or at all; and Armata’s estimates of expected operating losses, capital requirements and need for additional funding. Additional risks and uncertainties relating to Armata and its business can be found under the heading “Risk Factors” and elsewhere in Armata’s filings and reports with the SEC, including Armata’s Annual Report on Form 10-K filed with the SEC on March 21, 2024and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with respect thereto or any change in events, conditions or circumstances on which any such statement is based.
Media contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
(email protected)
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
(email protected)
212-915-2569
SOURCE: Armata Pharmaceuticals, Inc.
